Products
Ketotransdel® is comprised of a transdermal formulation of ketoprofen, an NSAID, and the Company's innovative patented proprietary Transdel™ drug delivery system. Ketotransdel® penetrates the skin barrier to reach the targeted underlying tissue where it exerts its prolonged localized anti-inflammatory effect.
This drug may minimize systemic exposure, therefore, resulting in fewer concerns pertaining to gastrointestinal, renal, cardiovascular and other adverse systemic effects, which are associated with orally administered NSAIDs.
This drug may help address certain safety concerns in the market and potentially provide physicians and patients with a much needed alternative for pain.
This drug may minimize systemic exposure, therefore, resulting in fewer concerns pertaining to gastrointestinal, renal, cardiovascular and other adverse systemic effects, which are associated with orally administered NSAIDs.
This drug may help address certain safety concerns in the market and potentially provide physicians and patients with a much needed alternative for pain.
Phase 3 Clinical Trial for Ketotransdel
Transdel Pharmaceuticals, Inc. is currently conducting a Phase 3 clinical trial for our lead product, Ketotransdel®, a novel analgesic and anti-inflammatory topical cream and is intended for use in the treatment of acute pain from musculoskeletal conditions.
The Company's randomized, double-blind, placebo controlled Phase 3 trial will evaluate the efficacy and safety of Ketotransdel® for the topical treatment of acute pain from soft tissue injuries and is being conducted at 30 sites in the United States. The Company expects to enroll approximately 350 patients, of which 50% will be provided Ketotransdel® and 50% a placebo vehicle. The Company expects that Ketotransdel® , if approved by the U.S. Food and Drug Administration, could become the first topical NSAID cream product in the United States for acute pain management. If and when the FDA approves Ketotransdel® for treatment of acute pain, we intend to pursue FDA approval of Ketotransdel™ for other indications, including osteoarthritis.
For further information regarding this clinical trial, please contact CATO research at (858) 452-7271
The Company's randomized, double-blind, placebo controlled Phase 3 trial will evaluate the efficacy and safety of Ketotransdel® for the topical treatment of acute pain from soft tissue injuries and is being conducted at 30 sites in the United States. The Company expects to enroll approximately 350 patients, of which 50% will be provided Ketotransdel® and 50% a placebo vehicle. The Company expects that Ketotransdel® , if approved by the U.S. Food and Drug Administration, could become the first topical NSAID cream product in the United States for acute pain management. If and when the FDA approves Ketotransdel® for treatment of acute pain, we intend to pursue FDA approval of Ketotransdel™ for other indications, including osteoarthritis.
For further information regarding this clinical trial, please contact CATO research at (858) 452-7271